Relapse · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants with relapse Risk ratio (M‐H, random, 95% CI) compared with glatiramer acetate (moderate certainty).
1 finding from 1 review
Number of participants with confirmed progression Risk ratio (M‐H, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants with confirmed progression Risk ratio (M‐H,… compared with glatiramer acetate (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants who dropped out for AEs Risk ratio (M‐H,… compared with glatiramer acetate (low certainty).
1 finding from 1 review
Mean number of active T2 lesions Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Mean number of new enhancing lesions Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Mean change in total T2‐hyperintense lesion load Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Mean change in total T1‐hypointense lesion load · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Relapse · Multiple sclerosis
It is very uncertain whether statins plus beta interferon changes number of participants with relapses at 12 months Number of… compared with beta interferon (very low certainty).
2 findings from 1 review
Number of participants with progression at 12 months3 ‐ not reported · Multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants with progression at 24 months Number of participants with progression at 24 months · Multiple sclerosis
It is very uncertain whether statins plus beta interferon changes number of participants with progression at 24 months Number of… compared with beta interferon (very low certainty).
1 finding from 1 review
Number of participants with new T2 or GELs at 12 months Number of participants with new T2 or GELs at 12 months · Multiple sclerosis
It is very uncertain whether statins plus beta interferon changes number of participants with new T2 or GELs at 12 months Number of… compared with beta interferon (very low certainty).
1 finding from 1 review
Number of participants with new T2 or GELs at 24 months3 ‐ not reported · Multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Change in disability Assessed by: EDSS · Multiple sclerosis
1 finding from 1 review
Intervention not reported
Pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512… (low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes interferon beta 1a‐1b No direct evidence (very low certainty).
1 finding from 1 review
RR 1.21 [0.66, 2.19]
1 participants
Very low
Intervention not reported
Interferon beta‐1b (Betaferon) (Direct evidence; 1 RCT; 372 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to lower interferon beta‐1b (Betaferon) (Direct evidence; 1 RCT; 372… (low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta‐1a (Avonex, Rebif) (Direct evidence; 3 RCTs; 1629 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower interferon beta‐1a (Avonex, Rebif) (Direct evidence; 3 RCTs; 1629… (moderate certainty).
1 finding from 1 review
RR 0.84 [0.78, 0.91]
1 study · 3 participants
Moderate
Intervention not reported
Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes interferon beta 1a‐1b No direct evidence (very low certainty).
1 finding from 1 review
RR 3.19 [0.31, 33.21]
1 participants
Very low
Intervention not reported
Interferon beta‐1b (Betaferon) (Direct evidence; 1 RCT; 372 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to lower interferon beta‐1b (Betaferon) (Direct evidence; 1 RCT; 372… (low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta‐1a (Avonex, Rebif) (Direct evidence; 2 RCTs; 1069 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in interferon beta‐1a (Avonex, Rebif) (Direct evidence; 2 RCTs; 1069… (low certainty).
1 finding from 1 review
RR 0.92 [0.73, 1.16]
1 study · 2 participants
Low